Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $57.07 in the prior trading day, Cytokinetics Inc (NASDAQ: CYTK) closed at $55.85, down -2.14%. In other words, the price has decreased by -$2.14 from its previous closing price. On the day, 0.97 million shares were traded. CYTK stock price reached its highest trading level at $57.22 during the session, while it also had its lowest trading level at $55.32.
Ratios:
Our goal is to gain a better understanding of CYTK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.39 and its Current Ratio is at 10.39. In the meantime, Its Debt-to-Equity ratio is 7.28 whereas as Long-Term Debt/Eq ratio is at 7.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 13, 2024, Downgraded its rating to Neutral and sets its target price to $60 from $85 previously.
On January 24, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $61 to $92.
Morgan Stanley Downgraded its Overweight to Equal-Weight on January 05, 2024, whereas the target price for the stock was revised from $60 to $90.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 26 ’24 when B LYNNE PARSHALL bought 5,000 shares for $57.26 per share.
PARSHALL B LYNNE sold 5,000 shares of CYTK for $286,300 on Aug 26 ’24. The Director now owns 20,600 shares after completing the transaction at $57.26 per share. On Aug 20 ’24, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 7,300 shares for $56.25 each. As a result, the insider received 410,638 and left with 125,004 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6571310592 and an Enterprise Value of 6304688640. For the stock, the TTM Price-to-Sale (P/S) ratio is 2099.46 while its Price-to-Book (P/B) ratio in mrq is 60.47. Its current Enterprise Value per Revenue stands at 2011.707 whereas that against EBITDA is -12.784.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is 0.26%, while the 200-Day Moving Average is calculated to be -8.24%.
Shares Statistics:
The stock has traded on average 1.70M shares per day over the past 3-months and 1065170 shares per day over the last 10 days, according to various share statistics. A total of 117.66M shares are outstanding, with a floating share count of 113.75M. Insiders hold about 3.32% of the company’s shares, while institutions hold 113.91% stake in the company. Shares short for CYTK as of 1722384000 were 17832699 with a Short Ratio of 10.97, compared to 1719532800 on 17377857. Therefore, it implies a Short% of Shares Outstanding of 17832699 and a Short% of Float of 23.200001.
